Showing results (201-210 of 227) with videos related to
Sort By:
Pageof 23
Lancet (London, England)|August 28, 2016
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trialLi Zhang, Yan Huang, Shaodong Hong, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2021
An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian CancerNing Li, Hualei Bu, Jihong Liu, et al.Translational Lung Cancer Research|February 10, 2023
Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV)Chong-Rui Xu, Qixun Chen, Chengzhi Zhou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2021
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III StudyShaodong Hong, Yaxiong Zhang, Gengsheng Yu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2020
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II TrialJianming Xu, Jie Shen, Shanzhi Gu, et al.The Lancet. Oncology|November 27, 2025
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 studyShukui Qin, Shanzhi Gu, Stephen L Chan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal JunctionJin Li, Shukui Qin, Jianming Xu, et al.Nature Communications|August 1, 2020
Purine metabolism regulates DNA repair and therapy resistance in glioblastomaWeihua Zhou, Yangyang Yao, Andrew J Scott, et al.Cell Regeneration (London, England)|January 14, 2025
Standard: Human gastric organoidsFan Hong, Ronghui Tan, Ting Wang, et al.The Oncologist|June 9, 2021
Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703)Yihebali Chi, Yongqian Shu, Yi Ba, et al.Pageof 23